Drug Profile
Leuprorelin - Tolmar
Alternative Names: Eligard; LA 2575; Leuprogel®; SOT-375; SOU 375Latest Information Update: 04 Nov 2018
Price :
$50
*
At a glance
- Originator QLT USA
- Developer Tolmar
- Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
- Mechanism of Action Gonadotropin releasing hormone stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Prostate cancer
- Phase III Precocious puberty
- Discontinued Endometriosis
Most Recent Events
- 05 Sep 2018 Tolmar completes a phase III trial in Precocious puberty (In children) in Canada, Chile, Mexico, Argentina, New Zealand (SC) (NCT02452931)
- 19 Feb 2018 TOLMAR Australia has been acquired by Mundipharma (China) Pharmaceutical
- 15 May 2017 Pooled pharmacokinetics data from four pivotal studies in Prostate cancer presented at the 112th Annual American Urological Association Meeting in Boston (AUA-2017)